Several pharmaceutical companies have explored transdermal delivery systems to avoid injections, but these formulations have not completed Phase III clinical trials or received FDA clearance
Lessons from the ProRx situation Whether or not your specific medication was affected by the ProRx recalls, the situation offers broader lessons applicable to anyone using compounded peptides
Without adjustments to training volume, intensity, and nutrition timing, recovery will be impaired
LINZESS should be taken 1 : On an empty stomach and at least 30 minutes prior to a meal At approximately the same time each day Clinical considerations 1 Duration of use is not limited Dosing adjustments for patients with renal or hepatic impairment are not required No drug-drug interactions are anticipated Negligible systemic availability INDICATIONS AND USAGE LINZESS (linaclotide) is indicated for the treatment of: irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older chronic idiopathic constipation (CIC) in adults functional constipation (FC) in pediatric patients 6 years of age and older IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE LINZESS is contraindicated in patients less than 2 years of age
Scenario 3: Perimenopausal woman on oral HRT switching to GLP-1 You are 47, in perimenopause, currently taking oral estradiol 1 mg daily and oral micronized progesterone 100 mg nightly
